Emactuzumab [1448221-67-7]
Cat# T76776-5mg
Size : 5mg
Marca : TargetMol
Emactuzumab
(Synonyms: RO 5509554, RG 7155) Copy Product InfoEmactuzumab(RG 7155) is a monoclonal antibody against colony-stimulating factor-1 receptor targeting tumor-associated macrophages (TAMs) Emactuzumab has antitumor activity and inhibits activation of colony-stimulating factor 1 receptor (CSF1R) Emactuzumab has a high affinity for CSF-1R with a Ki value of 0.2 nM. Emactuzumab blocks CSF-1R dimerization and can be used to study cancers such as diffuse tenosynovial giant cell tumor (dt-GCT).
Cas No. 1448221-67-7
For research use only—not for human use. No sales to individuals. Use as intended only.
Select Batch
Purity:98.1% (SDS-PAGE); 97.3% (SEC-HPLC)
Appearance:Liquid
Color:Transparent
COA SDS-PAGE SEC-HPLC ELISA Instruction Manual of Inhibitory Antibody
Product Information
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Emactuzumab(RG 7155) is a monoclonal antibody against colony-stimulating factor-1 receptor targeting tumor-associated macrophages (TAMs) Emactuzumab has antitumor activity and inhibits activation of colony-stimulating factor 1 receptor (CSF1R) Emactuzumab has a high affinity for CSF-1R with a Ki value of 0.2 nM. Emactuzumab blocks CSF-1R dimerization and can be used to study cancers such as diffuse tenosynovial giant cell tumor (dt-GCT). |
| In vitro | RG7155 (30 μg/mL; 6 days) induces cell death of in vitro-differentiated human M2-like macrophages.[2] Inducing cell death, RG7155 (0-10 μg/mL; 7 days) inhibited the viability of CSF-1-differentiated macrophages with an IC50 of 0.3 nM.[2] Emactuzumab, with a high affinity binding to human and cynomolgus CSF-1R (Kd = 0.2 nM), effectively prevents CSF-1R dimerization.[2] |
| In vivo | Emactuzumab (0.1、1、10、30 and 100 mg/kg; i.v.; once; male cynomolgus monkey) increased CSF-1 concentration in serum.[2] RG7155 (0, 30, and 100 mg/kg; i.v.; once weekly; for 2 weeks; male and female cynomolgus) Efficiently reduced CSF-1R and CD68+163+ macrophages in the liver (Kupffer cells) and colon of cynomologus monkeys.[2] |
| Endotoxin | <1.0 EU/mg |
| Synonyms | RO 5509554, RG 7155 |
| Reactivity | Human |
| Verified Activity | Immobilized Human CSF1R Protein (His) (TMPY-01037) at 1 μg/mL (100 μL/well) can bind Emactuzumab. The EC50 is 2.58 ng/mL.  |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | 1436 |
| Uniprot ID | P07333 |
| Target | CSF1R/M-CSFR/CD115 |
| Molecular Weight | 144.4 kDa |
| Cas No. | 1448221-67-7 |
| Isotype | Human IgG1 kappa |
| Recommended Isotype Control | Human IgG1 kappa, Isotype Control |
| Storage | Store at low temperature -20°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Product Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Si può anche essere interessati nei seguenti prodotti:
Cat#
Descrizione
Cond.
Priced
Si può anche essere interessati nei seguenti prodotti:
Cat#
Descrizione
Cond.
Priced